Based on its recent analysis of the high throughput multiplexing market, Frost & Sullivan recognizes IntelliCyt with the 2016 North American Frost & Sullivan Award for Product Leadership. IntelliCyt’s unique platform, the iQue® Screener, is an integrated system that is not only scalable, but offers an end-to-end solution to address researchers’ challenges. The platform provides fast, rich, multiplexed information about each cell while ensuring quality of the data obtained.
The iQue Screener platform is an integrated instrument, software, and reagent system that offers high throughout multiplexed analysis of cell and bead assays in industry-standard microplates. Its two-laser platform, with six detection parameters per cell and the ability to analyze 96 and 384 well microplates, proved highly popular, especially in the pharmaceutical and biotech industries. An enhanced version of the product, the iQue Screener HD, was launched with the added capability to analyze 1536 well microplates, which are used in large-scale, high throughput screening operations. Additionally, IntelliCyt has a higher parameter product, the iQue Screener PLUS, with three lasers that can measure up to 15 detection channels per cell.
“The biggest differentiators of the iQue Screener are its speed and throughput when analyzing multiple samples in 96, 384, and even 1536 well microplates,” said Frost & Sullivan Research Analyst Aish Vivekanandan. “The iQue Screener’s proprietary rapid sampling technique employs a continuous, air gap separated, stream of samples. This technique enables researchers to use as little as 1 µl of sample from each well and perform the analysis many times faster than traditional flow cytometers.”
IntelliCyt’s iQue Screener can detect individual cells and/or beads and make multiplex measurements on each. The sample processing time can be as little as 3 minutes for a 96 well plate and 12 minutes for a 384 well plate. The same analysis can take hours with competing analyzers.
The iQue Screener is particularly useful in cases where cells are in limited supply because it makes it possible for researchers to obtain quality data from micro-volume samples. This allows the user to run hundreds of tests using the same sample, while a standard flow cytometer can only run 5 to 10 tests. Furthermore, by miniaturizing the sample volume, the iQue Screener lowers the amount of reagents needed, thereby lowering reagent costs per test.
The iQue Screener has distinguished itself in the market, not just with its core platform, but also with its ForeCyt® software. The software boasts various features including unique plate-level analysis and visualization tools. It offers a multi-user, multi-instrument data storage and management solution that is secured through encrypted network communication.
”IntelliCyt’s ForeCyt software allows for simple deployment and installation with personalized infrastructures through flexible IT layouts,” noted Vivekanandan. “Apart from flexibility, the IntelliCyt’s software offers interactive gating and real-time results re-analysis for fast and easy assay optimization. The distinctive “profile mapping” feature presents valuable data on cell processes or interactions to help obtain vital insights into diseases and their possible cures.”
For the clear value that IntelliCyt’s iQue Screener brings to the market, Frost & Sullivan is pleased to present the company with the 2016 North American Frost & Sullivan Award for Product Leadership.
Each year, Frost & Sullivan presents this award to the company that has developed a product with innovative features and functionality, gaining rapid acceptance in the market. The award recognizes the quality of the solution and the customer value enhancements it enables.
Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
IntelliCyt Corporation (intellicyt.com) manufactures and sells instrumentation, software and reagents that facilitate the study of cells and their components to gain a better understanding of normal and disease processes. This information speeds the discovery and development of new drugs and provides new insight for the diagnosis of diseases. IntelliCyt’s products are used worldwide throughout the pharmaceutical and biotechnology industries and in nonprofit research labs.
About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion | Join Us: Join our community | Subscribe: Newsletter on "the next big thing" | Register: Gain access to visionary innovation.